Forrest Swann, MD
Cornea and External Diseases Specialist · Waco, TXNPI 1407291420
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 37.2% of the total. Among cornea and external diseases specialist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $172.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$41K
- Bausch & Lomb Americas Inc.$31K
- Johnson & Johnson Surgical Vision, Inc.$9K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$9K
- Carl Zeiss Meditec, Inc.$4K
- Lensar, Inc.$3K
- plus $14K from 33 others
What the payments were for
- Consulting fees$31,65028%
- Speaking & faculty fees$46,63042%
- Travel & lodging$7,3217%
- Food & beverage$25,42923%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$40,651
- enVista MX60 IOL$24,455
- STELLARIS ELITE$20,926
- Crystalens Accommodating IOL (AT-52AO)$20,351
- Trulign IOL$20,351
- Tecnis Simplicity$7,208
- Tecnis IOL$7,064
- LOTEMAX SM$6,629
- Akreos AO IOL$6,047
- LENSAR LASER SYSTEM$2,316
- XIIDRA$2,151
- MIEBO$2,151
- IOLMaster 700$1,650
- VERACITY SURGICAL$1,650
- DURYSTA$924
- STELLARIS$845
- RXSIGHT CONTACT LENS$737
- RXSIGHT INJECTOR CARTRIDGE$737
- RXSIGHT INJECTOR HANDPIECE$737
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$737
How this compares
$111,091 in reported general payments places this provider in the 95th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 34 | $1,289,391 |
| MieboPerfluorohexyloctane/Pf | 150 | $116,078 |
| ProlensaBromfenac Sodium | 219 | $76,847 |
| RestasisCyclosporine | 30 | $31,570 |
| XdemvyLotilaner | 13 | $24,427 |
| Lotemax SmLoteprednol Etabonate | 80 | $20,504 |
| VyzultaLatanoprostene Bunod | 53 | $19,790 |
| LumiganBimatoprost | 32 | $15,842 |
| Bromfenac Sodium | 79 | $13,664 |
| Prednisolone Acetate | 378 | $12,508 |
| IlevroNepafenac | 24 | $8,764 |
| Ofloxacin | 712 | $8,226 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 436 | $6,669 |
| Latanoprost | 589 | $5,064 |
| RhopressaNetarsudil Mesylate | 13 | $3,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $121 | $1,289,39134 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $30,848 | $135,869203 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $8,819 | $97,351299 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,568 | $53,97494 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $295 | $24,42713 claims |
| NovartisIlevro | $233 | $8,76424 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $12 | $3,99013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in Waco
- Stella KimHouston$58K
- Rachel GelmanMcAllen$54K
- Ravi PatelRound Rock$9K
- Jeremy BartleyDallas$8K
- Margaret Wang FrenchDallas$5K
- Elizabeth UriasHouston$5K
- Shaam MahasnehMansfield$4K
- Margaret HubbellTexarkana$4K
- Ardalan SharifiGalveston$3K
- Amar BhatBeaumont$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.